Acousia Therapeutics is a biotech company working to identify small molecules for treatment of hearing loss. The Company develops a technology which will help to replace lost hair cells by cellular regeneration originating from supporting cells. It works on drugs for local application, which will restore hearing in patients who have lost their hearing ability due to various reasons, e.g. noise trauma, treatment with ototoxic drugs or sudden deafness. In addition, this therapy will have the potential to treat the age-related decrease in hearing capacity.
Acousia Therapeutics total Funding
Acousia Therapeutics latest funding size
Time since last funding
|3 years ago|
Acousia Therapeutics investors
|KfW Bankengruppe, LBBW Venture Capital GmbH, Boehringer Ingelheim Venture Fund, Bregua Corporation, Kreditanstalt für Wiederaufbau, Creathor Ventures, Axxam|
When was Acousia Therapeutics founded?
Acousia Therapeutics was founded in 2017.
Who are Acousia Therapeutics key executives?
Acousia Therapeutics's key executives are Michael Bos and Tim Boelke.
Who are Acousia Therapeutics competitors?
Competitors of Acousia Therapeutics include Nordic Nanovector, Brii Biosciences and Prevail Therapeutics.
Where is Acousia Therapeutics headquarters?
Acousia Therapeutics headquarters is located at Sindelfinger Straße 3 , Tübingen.
Where are Acousia Therapeutics offices?
Acousia Therapeutics has an office in Tübingen.
How many offices does Acousia Therapeutics have?
Acousia Therapeutics has 1 office.
Receive alerts for 300+ data fields across thousands of companies